Palisade Bio, Inc. Common Stock
Here’s whether Palisade Bio, Inc. Common Stock (PALI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 37 — healthy momentum range; strong 1-year return of +147.8%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.02% over 10 days); 3-month momentum negative (-14.1%). Currently 40.1% off its 52-week high. Score: -3/7.
PALI is trading below its 200-day MA ($1.75) — a key warning sign the longer-term trend is under pressure. An RSI of 37.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +147.8% compares to +22.9% for SPY (beat the market by 125.0%). The current 40.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.